Oropharyngeal Cancer
95
15
31
38
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
19 trials with published results (20%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
5.3%
5 terminated out of 95 trials
88.4%
+1.9% vs benchmark
7%
7 trials in Phase 3/4
50%
19 of 38 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 38 completed trials
Clinical Trials (95)
Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
Integrated Cancer Repository for Cancer Research
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
Evaluation of the Photobiomodulation Using LED Lamp for Curative Treatment of Radio-induced Mucositis.
Prospective Study for the Prognostic and Predictive Role of Circulating Tumor Cells in Patients With Oropharyngeal Squamous Cell Carcinoma: CTCO (Circulating Tumor Cells in the Oropharynx)
Depression and Adherence in Head and Neck Cancer
Enhancing Self Care Among Oral Cancer Survivors: The Empowered Survival Trial
Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy for HPV + Oropharyngeal Cancers
TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring
Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma